|
AVE-1625
|
DB05750 |
[AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.] |
|
4'-Hydroxyflavanone
|
DB04429 |
|
|
CYT007-TNFQb
|
DB05758 |
[CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low
amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.] |
|
Alpha-Methyl-N-Acetyl-D-Glucosamine
|
DB04426 |
|
|
4-Methyl-N-[(2S)-1-oxo-3-phenyl-1-[[(3S)-1-phenyl-5-(phenylmethoxysulfamoyl)pentan-3-yl]amino]propan-2-yl]piperazine-1-carboxamide
|
DB04427 |
|
|
DNB-001
|
DB05757 |
[DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma. In preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve.] |
|
PAC-113
|
DB05756 |
[PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. In vitro studies demonstrate that it has potent anti-fungal activity against the Candida albicans, including drug-resistant HIV patient isolates. PAC-113 is targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction.
] |
|
RPR128515
|
DB04424 |
|
|
7,8-Dihydroneopterin
|
DB04425 |
|
|
BF-37
|
DB05755 |
[BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.] |
|
IPH 1101
|
DB05754 |
[IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform] |
|
2-Amino-4-Mercapto-Butyric Acid
|
DB04422 |
[A thiol-containing amino acid formed by a demethylation of METHIONINE. [PubChem]] |
|
Coproporphyrin I containing CO(III)
|
DB04423 |
|
|
VSF-173
|
DB05753 |
[VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.] |
|
ALKS 27
|
DB05752 |
[ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD). Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.] |
|
Nicotinamide adenine dinucleotide 3-pentanone adduct
|
DB04421 |
|
|
RP01
|
DB05751 |
[RP01 is a novel anti-IgE immunotherapy for allergic individuals. It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. It could offer benefit to millions of asthma and allergy patients.] |
|
Alpha-L-Fucose
|
DB04473 |
|
|
Alpha-L-Arabinose
|
DB03142 |
|
|
Nonan-1-Ol
|
DB03143 |
|
